Pharma And Health Reform: Staying On The Sidelines Works Out
The failure of the GOP effort to repeal the Affordable Care Act came after a lot of health care stakeholders warned that proposals in the Senate would lead to a disaster. The pharmaceutical industry maintained its silence on the bill – and probably ends up as one of the winners as the dust settles.
You may also be interested in...
The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.
As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.
The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.